Clinical Trial Update: Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of a JAK3 inhibitor to prevent acute rejection in kidney transplant patients; the study has completed and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• JAK3 inhibitor (JAK3 inhibitor)

Snippet

Sponsor: Pfizer | Conditions: Kidney Transplantation | Phase 2 | Status: COMPLETED | Results posted: 2013-03-14